The MCL1-specific inhibitor MIK665 has shown activity when studied as a single agent in MCL cell lines and patient samples and has shown significant synergism with venetoclax in several PDX models of MCL [32, 33]. The gene discussed is MCL1; the disease is mantle cell lymphoma.